摘要:

The safety and efficacy of patient-controlled analgesia for the long-term control of cancer pain was tested prospectively. Respiratory rates, mental status, and pain relief were recorded at baseline and compared with those during the study period. Patients had a lower analgesic demand (i.e., self-administered less morphine during the nighttime); specifically, dosing declined48% from the daytime level. Respiratory rates did not change appreciably during the study and no cases of significant respiratory depression were encountered. Patients self-administered sufficient morphine to produce adequate but not complete pain relief in almost all trials. Pain relief was safely achieved by both intravenous and subcutaneous routes of administration in both the inpatient and outpatient settings. Mean 24-h morphine use stayed relatively constant even for patients receiving more than 2 weeks of treatment. In conclusion, patient-controlled analgesia is effective and safe therapy for the long-term control of severe cancer pain.

ISSN:0735-7907    

DOI:10.3109/07357909209024792

出版商:Taylor&Francis    

年代:1992

数据来源: Taylor

摘要:

Outpatients (n = 15) with metastasizing far advanced colorectal cancers received immunotherapy consisting of low-dose cyclophosphamide (LDCY) 300 mg/m2every 28 days i.v., thymostimulin 30 mg/m2, days 3-10 after low-dose cyclophosphamide i.m. once daily, then twice a week, and echinacin 60 mg/m2together with thymostimulin i.m. All patients had had previous surgery and/or chemotherapy and had progressive disease upon entering the study. Two months after onset of therapy a partial tumor regression was documented in one and a stable disease in 6 other patients by abdominal ultrasonography, decrease of the tumor markers carcinoem-bryonic antigen (CEA), CA 19-9, CA 15-3, and/or chest roentgenography, which may also be attributed to the natural course of disease. Mean survival time was 4 months, 2 patients survived for more than 8 months. Immunotherapy was well tolerated by all patients without side effects.

ISSN:0735-7907    

DOI:10.3109/07357909209024793

出版商:Taylor&Francis    

年代:1992

数据来源: Taylor

摘要:

Fifty-six untreated patients with inoperable squamous cell carcinoma of the head and neck were treated with carboplatin 70 mglm2i.v. daily on days 1-5 and 29-33 in combination with simultaneous conventional radiation up to a target volume dose of 50 Gy. Depending on tumor response and upon recommendation of surgeons, 21 of 56 patients underwent surgery after a radiation dose of 50 Gy and two courses of carboplatin. Patients who showed pCR after surgery received no further radiotherapy. In all other patients radiotherapy was continued using a shrinking field technique up to a target absorbed dose of 70-74 Gy. Combined modality induced 66% complete remission (CR) and an overall response rate of 98%. After completion of the whole treatment program (combined modality±surgery) 53 (94%) of the 56 patients were disease free. The median survival for all patients is 25+ months and the percentage of two-year survivors is 53%. Myelosuppression was the most frequent toxicity, but rarely was severe; leukopenia and thrombocytopenia of WHO grade 3 occurred in 21% of the patients. No other toxicities above WHO grade 2 occurred. Nephrotoxicity, neurotoxicity and ototoxicity were not seen. The addition of carboplatin did not increase the rate of surgical complication over that expected for preoperative radiotherapy. Two patients died of pulmonary embolism after surgery. Combined modality with carboplatin and simultaneous radiation is a highly active and well-tolerated regimen for untreated patients with inoperable squamous cell carcinoma of the head and neck.

ISSN:0735-7907    

DOI:10.3109/07357909209024794

出版商:Taylor&Francis    

年代:1992

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357909209024795

出版商:Taylor&Francis    

年代:1992

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357909209024796

出版商:Taylor&Francis    

年代:1992

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357909209024797

出版商:Taylor&Francis    

年代:1992

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357909209024798

出版商:Taylor&Francis    

年代:1992

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357909209024799

出版商:Taylor&Francis    

年代:1992

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357909209024800

出版商:Taylor&Francis    

年代:1992

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357909209024801

出版商:Taylor&Francis    

年代:1992

数据来源: Taylor